Director reinvests dividends into Quest Diagnostics (NYSE: DGX) stock
Rhea-AI Filing Summary
Quest Diagnostics director Timothy L. Main reported a small acquisition of 21 shares of common stock on 2026-07-22 at $206.81 per share. The shares were acquired through a broker-administered dividend reinvestment plan and are eligible for deferred reporting under Rule 16a-6, though he chose to report early. After this transaction, he directly holds 22,460 shares and indirectly holds 5,000 shares through a trust.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 21 shares
Net Buy
2 txns
Insider
MAIN TIMOTHY L
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Small Acquisition | Common Stock F1 | 21 | $206.81 | $4K |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 22,460 shares (Direct);
Common Stock — 5,000 shares (Indirect, by Trust)
Footnotes (1)
- F1. Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4.
Key Figures
Shares acquired: 21 shares
Per-share price: $206.81 per share
Direct holdings after transaction: 22,460 shares
+2 more
5 metrics
Shares acquired
21 shares
Small acquisition under Rule 16a-6 on 2026-07-22
Per-share price
$206.81 per share
Price for the 21 shares acquired via dividend reinvestment
Direct holdings after transaction
22,460 shares
Direct ownership of Quest Diagnostics common stock following the acquisition
Indirect holdings by trust
5,000 shares
Shares reported as indirectly owned, nature of ownership listed as by Trust
Transaction date
2026-07-22
Date of the small acquisition reported on Form 4
Key Terms
dividend reinvestment plan, Rule 16a-6, Form 5
3 terms
dividend reinvestment plan financial
"acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker"
A dividend reinvestment plan lets shareholders automatically use cash dividends to buy more shares of the same company instead of receiving the money. It matters to investors because it turns regular payouts into a steady way to grow ownership and take advantage of compound returns—like having your savings automatically buy additional slices of a pie over time—while often reducing transaction costs and smoothing purchase timing.
Rule 16a-6 regulatory
"eligible for deferred reporting on Form 5 under Rule 16a-6"
Form 5 regulatory
"eligible for deferred reporting on Form 5 under Rule 16a-6"
A Form 5 is an annual report filed with the U.S. securities regulator by company insiders—such as officers, directors and large shareholders—to disclose any equity transactions or holdings that were missed or deferred during the year. Think of it as an end-of-year ledger adjustment that shows final insider ownership and late-reported trades; investors use it to verify insider confidence, detect possible conflicts of interest, and spot unusual patterns in insiders’ buying or selling.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Timothy L. Main report for Quest Diagnostics (DGX)?
Director Timothy L. Main reported a small acquisition of 21 shares of Quest Diagnostics common stock. The shares were obtained on 2026-07-22 via a broker-administered dividend reinvestment plan and are classified as a small acquisition under Rule 16a-6.
Does the Quest Diagnostics (DGX) Form 4 indicate use of a Rule 10b5-1 trading plan?
No. The filing’s Rule 10b5-1 checkbox is marked as not affirmed, indicating the reported transaction was not designated as occurring under a Rule 10b5-1 trading plan. The acquisition instead arose from a routine dividend reinvestment arrangement.
How are indirect holdings reported for Timothy L. Main in Quest Diagnostics (DGX)?
Indirect ownership is reported as 5,000 shares held "by Trust". This line is presented as a holding entry rather than a new transaction, distinguishing these trust-held shares from the directly owned shares affected by the dividend reinvestment acquisition.